RecruitingPrimary outcome measures: rate of progression of TTR cardiac amyloidosis (strain echocardiography)Secondary outcome measures: number of patients with adverse events to the medications over the period of therapy (18 months), evaluate general and health related QoL in senile and familial TTR amyloidosis subjects. This evidence concerns the gene TTR and cardiac amyloidosis.